Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Expands Leadership Team with Appointment of Key Regulatory Leader
AGTC Appoints Regulatory Expert, Janet C. Rae , RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials - - Company on track to provide multiple data readouts for its XLRP
View HTML
Toggle Summary AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules - GAINESVILLE, Fla. and CAMBRIDGE, Mass.
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT
-Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting
View HTML
Toggle Summary AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- -Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- -Data from a subset of Group 4 patients available for
View HTML
Toggle Summary AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass. , May 03, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
View HTML
Toggle Summary AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Visionary science for life changing cures.